Get them while they are hot before the market opens! Exelixis, Inc. (NASDAQ: EXEL) shares rose 13.74 percent to $4.14 in pre-market trading on its Q4 earnings call and the announcement of an exclusive licensing agreement, with Ipsen (OTC: IPSEY), for the commercialization and further development of cabozantinib, Exelixis’ main oncology drug. The company retrieved a fourth quarter net loss of $0.19 per share on revenue of $9.9 million. 21Vianet Group Inc (NASDAQ: VNET) rose 6.72 percent to $18.74 in pre-market trading. 21Vianet Group is expected to release its Q4 financial results on March 10, 2016. Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares rose 6.40 percent to $8.65 in pre-market trading after the company reported upbeat Q4 results. Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares rose 6.32 percent to $7.23 in pre-market trading. H.C. Wainwright initiated coverage on Celldex Therapeutics with a Buy rating and a $25.00 price target. JD.Com Inc(ADR) (NASDAQ: JD) shares rose 3.19 percent to $26.53 in the pre-market trading session after the company reported upbeat Q4 results.